The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer

Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer

“…However, for patients with platinum/taxane (especially paclitaxel/carboplatin)-refractory recurrent epithelial ovarian cancer, a standard treatment regimen has yet to be determined. In general, these patients have received single-agent chemotherapy without platinum agents, such as irinotecan, 11 topotecan, 12,13 liposomal doxorubicin, 14,15 docetaxel, 16,17 oral etoposide, 18 and gemcitabine. 2,3,19-23 Based on a review of nonrandomized phase II studies, Markman et al 24 reported that the median survival following single-agent chemotherapy in patients with platinum and taxane resistance was approximately 6 months, but they also reported that 27% of the patients survived for 12 months or longer following singleagent salvage chemotherapy.…”

Phase II Clinical Study of the Combination Chemotherapy Regimen of Irinotecan Plus Oral Etoposide for the Treatment of Recurrent Ovarian Cancer (Tohoku Gynecologic Cancer Unit 101 Group Study)

“…The eligibility criteria were as follows: patients (1) with histologically or cytologically confirmed diagnosis of ovarian cancer; (2) with recurrent ovarian cancer who had been treated previously with platinum and taxane agents; (3) with a measurable or evaluable lesion (including serum levels of CA125); (4) with an Eastern Cooperative Oncology Group performance status of 0, 1, or 2; (5) between 20 and 75 years of age; (6) who fulfilled the following criteria for hematological and biochemical parameters (white blood cell count, Q3000/mm 3 ; absolute neutrophil count, Q1500/mm 3 ; platelet count, Q100,000/mm 3 ; hemoglobin, Q9.0 g/dL; aspartate aminotransferase and alanine aminotransferase levels, e2 times the upper limit of the institutional normal range; serum total bilirubin, e1.5 mg/dL; serum creatinine, e1.5 mg/dL; creatinine clearance, Q50 mL/min; (7) with an estimated life expectancy of at least 2 months; and (8) who had voluntarily provided written consent for participation in this study.…”

“…Based on the aforementioned viewpoints, combination chemotherapy for patients with platinum and taxane drug resistance requires a regimen with a reduced toxicity and increased efficacy. In a study conducted by Matsumoto et al,7 in which irinotecan (100 mg/m 2 ), a topoisomerase-I inhibitor, was administered alone on days 1, 8, and 15 every 4 weeks to patients with platinum-and taxane-resistant ovarian cancer, the response rate was 29%. In Europe and the United States, studies have been conducted using etoposide, a topoisomerase-II inhibitor.…”

Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series

“…Irinotecan (CPT), a topoisomerase-1 inhibitor, has modest activity for patients with Pt-R ROC (15,16), and has synergic effects in combination with cisplatin (CPT-P) in vitro (17). Furthermore, the combination of CPT and CPT-P was reported to be effective for patients with Pt-R ROC (18,19).…”